²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°é

English

½ÓÊܶ©»õ£¡²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éÉúÎXa²â¶¨ÊÔ¼ÁºÐ»ñµÃÒ½ÁÆÆ÷еע²áÖ¤£¡

Ðû²¼ÓÚ£º2023-08-09

ÎÄÕÂȪԴ£º[ÖÐÎÄ]²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éÉúÎï



¹ÙÐû


²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éÉúÎXa£¨·¢É«µ×Îï·¨£©Ë³ËìÈ¡µÃ±±¾©ÊÐÒ©Æ·¼àÊÓ¹ÜÀí¾Ö½ÒÏþµÄ¡¶Ò½ÁÆÆ÷еע²áÖ¤¡·¡£




 ¿¹Xa²â¶¨ÊÔ¼ÁºÐ

·¢É«µ×Îï·¨





µã»÷Éó²é´óͼ





ǰÑÔ

ÏÖÔÚ £¬¾²ÂöѪ˨˨ÈûÐÔ¼²²¡£¨venous thromboembolism, VTE£©ºÍ¶¯ÂöѪ˨˨ÈûÐÔ¼²²¡³ÉΪµ¼ÖÂÈ«ÇòÉú³ÝéæÃüµÄµÚһλԵ¹ÊÔ­ÓÉ¡£´ó´ó¶¼¾²ÂöѪ˨ÓÉÓÚûÓÐÖ¢×´Ò×±»Â©Õï¡¢ÎóÕï £¬µ«VTEÊÇ¿ÉÒÔÔ¤·ÀµÄ £¬¿¹Äý¾ÍÊÇÔ¤·ÀºÍÖÎÁƵĻù´¡¡£¿ÉÊÇÔõÑù×èÖ¹¿¹ÄýÖÎÁƵ¼ÖµijöѪÐÔΣº¦ £¬¡¶ÖйúѪ˨ÐÔ·ÀÖÎÖ¸ÄÏ¡·£¨2018£©¹ØÓÚ²î±ð¿¹ÄýÒ©Îï¸ø³öÁËÏà¹ØµÄ¼à²âÖ¸±ê¡£


  • ÈôÓ¦ÓÃUFHÖÎÁÆ £¬ÍƼöÒ»Á¬¾²Âö¸øÒ©²¢Æ¾Ö¤»î»¯²¿·ÖÄýѪøԭʱ¼ä£¨APTT£©¼à²âЧ¹ûµ÷Àí¼ÁÁ¿ £¬Ö±ÖÁAPTTÑÓÉìÖÁ¿¹ÄýǰµÄ1.5~2.5±¶ £¬»òµÖ´ïÏ൱ÓÚѪ½¬UFHˮƽ0.3~0.7 U/ml ʱµÄ¿¹ XaÒò×Ó£¨FXa£©»îÐÔˮƽ¡¾1C¡¿¡£

  • ÖðÈÕÐè´ó¼ÁÁ¿UFHÖÎÁƶøAPTT²»´ï±êʱ £¬ÍƼöͨ¹ý¼à²â¿¹FXaµÄˮƽָµ¼ÓÃÒ©¼ÁÁ¿¡¾1B¡¿¡£

  • Ó¦ÓÃLMWHÖÎÁƼ±ÐÔDVTʱ £¬ÈôºÏ²¢ÑÏÖØÉö¹¦Ð§²»È«£¨¼¡ôûɨ³ýÂÊ<30 ml/minʱ £¬É÷ÓÃLMWH£© £¬½¨ÒéLMWH¼õÁ¿²¢¼à²â¿¹FXa»îÐÔ¡¾2C¡¿¡£



¡¶¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÖÎÁÆÖйúר¼Ò¹²Ê¶£¨2015£©¡·¶ÔµÍ·Ö×Ó¸ÎËØµÄÖÎÁƹæÄ£Ò²¸ø³öÁ˽¨Ò飺ÈÑÉïʱ´úÐè°´ÆÚ¼à²â¿¹Xa»îÐÔ £¬Æä·åÖµÓ¦ÔÚ×î½üÒ»´Î×¢Éäºó4h²â¶¨ £¬¹ÈÖµÓ¦ÔÚÏ´Î×¢Éäǰ²â¶¨ £¬¿¹Xa»îÐÔÄ¿µÄ¹æÄ£Îª0.6¡«1.0 IU£¯ml £¬ÌìÌì¸øÒ©1´ÎµÄÄ¿µÄ¹æÄ£Îª1.0¡«2.0 IU£¯ml¡£


Ðí¶à»ú¹¹Ê¹Óÿ¹XaÒò×Ó»îÐԲⶨ×÷Ϊ½ð±ê×¼²âÊÔ £¬ÒÔ¼à²âºÍµ÷½âÖÎÁÆÐÔδ·Ö×é¸ÎËØºÍµÍ·Ö×Ó¸ÎËØÖÎÁƵĹÜÀí¡£

¡ª¡ª¡¶ELSO Anticoagulation Guideline¡·


ÏÔÉ«¿¹XaÒò×ӲⶨÊÇÏÖÔÚ¼à²âµÍ·Ö×Ó¸ÎËØºÍ»Ç´ï¸Î¿ûÄÆÖÎÁƵĽð±ê×¼¡£

¡ª¡ª¡¶Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux¡·


ʹÓÃUFHºÍLMWH¾ÙÐп¹ÄýÖÎÁÆÊ± £¬ÏÂÁÐÈËȺÐèÒª¾ÙÐмà²â£º

#  Ó¤Ó×¶ùºÍ¶ùͯ

#  ÀÏÈË£¨ÄêËꣾ85Ë꣩

#  ÌåÖØÒì³£Õß

#  ¼¡ôûɨ³ýÂÊÔÚ15¡«30 mL£¯minµÄÂýÐÔÉö²¡Õß

#  ÈÑÉ︾Ů

#  ÓгöѪΣº¦µÄ»¼ÕßµÈ


¿¹Xa»îÐÔ¼ì²â


¼ì²âÔ­ÀíΪ£ºÑù±¾ÖеĸÎËØÓ뿹ÄýѪøÍŽáÐγɸ´ºÏÎïºó £¬»áÓ벿·ÖXaÍŽá £¬²¢Ê¹Õⲿ·ÖXaʧ»î¡£Ê£ÓàµÄXa¿É½«ºÏ³ÉµÄÏÔÉ«µ×ÎïÆÊÎö±¬·¢¶ÔÏõ»ù±½°·£¨PNA£© £¬PNAÔÚ405nm´¦ÓÐ×î´óÎüÊÕ·å £¬Í¨¹ý²â¶¨¶ÔÏõ»ù±½°·µÄÐγÉÁ¿À´ÅÌËã¸ÎËØ»îÐÔ¡£


¿¹Xa»îÐÔ¼ì²âÔ­Àíͼ



ÊÔ¼ÁÐÔÄÜ


²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°é¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©Í¨¹ýÑÕɫת±äÀ´²â¶¨¿¹ÄýÇ¿¶È/ѪҩŨ¶È £¬ÏßÐÔ¿í £¬¿¹×ÌÈÅÄÜÁ¦Ç¿ £¬Ï¸ÃÜ¶È¸ß £¬ÓëÊг¡Ö÷Á÷³§¼ÒÊÔ¼ÁÏà¹ØÐÔÓÅÒì £¬R2£¾0.95 £¬¿ÉÖª×ãÁÙ´²¼ì²âÐèÇó¡£


£¨Êý¾ÝȪԴ£º¿¹Xa¶àÖÐÐÄÒ½ÔºÑù±¾±È¶ÔÊý¾Ý£©


½ð˹¶û¿¹XaÊÔ¼Á¿ÉÒÔÖª×ãÁÙ´²Ô¤ÆÚÓÃ;£º

½ð˹¶û¿¹XaÊÔ¼ÁºÐͨË׸ÎËØÏßÐÔ¿ÉÒÔ×öµ½4IU/mL £¬²»µ«¿ÉÒÔÖª×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL £¬Í¬Ê±¿ÉÒÔÖª×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÇó¡£


¿¹×ÌÈÅÄÜÁ¦Ç¿£º

²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°é¿¹XaÊÔ¼ÁºÐ²¿·ÖÖ¸±ê £¬¿¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á¡£





С½á

¿¹Xa»îÐÔÊÔÑé¿ÉÓÃÓÚUFH¡¢LMWH¡¢»Ç´ï¸Î¹ïÄÆ¡¢Ö±½ÓFXaÒÖÖÆ¼ÁµÈ¶àÖÖÒ©ÎÄýÇ¿¶È/ѪҩŨ¶ÈµÄ²â¶¨¡£

4¼ÒÈý¼×Ò½ÔºÅäºÏ¼ÓÈëÁËÖйúÑо¿ÐÍҽԺѧ»áµÄ¡°¹ú²ú¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©¶àÖÐÐÄÏîÄ¿ÐÔÄÜÆÀ¼Û¡±£¨ÏîÄ¿±àºÅ£ºY2021FH-XSYZX04£©¿ÎÌâ £¬¾­¶àÖÐÐÄʵÑéЧ¹ûÂÛÖ¤£º

£¨1£©¹ú²ú¿¹XaºÍ±ÈÕÕÊÔ¼ÁµÄ²âÖµµÄÏà¹ØÐÔÓÅÒ죺ÎÞÂÛÊÇͨË׸ÎËØÕվɵͷÖ×Ó¸ÎËØ £¬²âÖµÏà¹ØÐÔ¾ùÔÚR2£¾0.95 £¬¿ÉÖª×ãÁÙ´²¼ì²âÐèÇó £»

£¨2£©¹ú²ú¿¹XaÊÔ¼Á¿ÉÒÔÖª×ãÁÙ´²Ô¤ÆÚÓÃ;£º²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°é¿¹XaÊÔ¼ÁºÐͨË׸ÎËØÏßÐÔ¿ÉÒÔ×öµ½4IU/mL £¬²»µ«¿ÉÒÔÖª×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL £¬Í¬Ê±¿ÉÒÔÖª×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÇó £»

£¨3£©¹ú²ú¿¹XaÊÔ¼ÁÐÔÄÜÆÀ¼ÛÓÅÒì £¬ÎªÁÙ´²Ìṩ¹ú²úÌæ»»µÄÑ¡Ôñ£ºÐÔÄÜÆÀ¼ÛÊý¾ÝÏÔʾ £¬²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°é¿¹XaÊÔ¼ÁºÐµÄ¸÷ÏîÐÔÄÜÓÈÆäÊÇÔÚ¿¹×ÌÈÅÄÜÁ¦·½Ãæ £¬¶ÔÖ±½Óµ¨ºìËØºÍѪºìÂѰ׵Ŀ¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á¡£



¡¶¿¹Xa¶àÖÐÐÄЧ¹û»ã±¨ÓëÆÊÎö¡·

ԢĿͨµÀ


PC¶ËÊäÈëÏ·½Á´½Ó¼´¿ÉµÇ¼ÄýÑªÔÆ¿ÎÌÃÆ½Ì¨ £¬Ô¢Ä¿ÊÓÆµ£º

https://vfs.xet.tech/s/2YYnDS

H5¶Ëʶ±ðÏ·½¶þάÂë £¬¼´¿ÉÌø×ªÖÁÊÓÆµÒ³Ã棺




²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éѪÄý¼ì²âϵͳ


²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éÉúÎïÊÇÖйúÁìÏȵÄÁÙ´²ÌåÍâÕï¶Ï²úÆ·Óë·þÎñ¹©Ó¦ÉÌÖ®Ò» £¬ÏÖÔÚÓµÓÐ×ÔÖ÷Ñз¢µÄÈ«×Ô¶¯ÄýѪ¼ì²âÆÊÎöÒÇMDC7500ºÍMDC3500ÒÔ¼°µÂ¹úÔ­×°Èë¿ÚµÄCoatron5000¡¢Coatron3000ºÍCoatron1800 £¬×¨ÒµÅäÌ×µÄÄýѪ¼ì²âÊÔ¼ÁÔÚÖª×ã×ÔÓмì²âϵͳµÄͬʱҲÄÜÍêÉÆÆ¥ÅäÖ÷Á÷ѪÄý¼ì²âϵͳ £¬Öª×ã²î±ð¿Í»§µÄÐèÇó £¬ÎªÁÙ´²ÌṩÖÜÈ«µÄѪ˨ÓëֹѪʵÑéÊÒ½â¾ö¼Æ»®¡£




²Î¿¼ÎÄÏ×

[1] ÖлªÒ½Ñ§»áÒâѪ¹Ü²¡Ñ§·Ö»á·ÎѪ¹Ü²¡Ñ§×é.¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÖÎÁÆÖйúר¼Ò¹²Ê¶(2015)[J].ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾,2016,44(3):197-211.

[2] ÀµÓîÒ¢,Àî¹ðɺ,ÍõÖ¾Ã÷,µÈ.¿¹Xa»îÐÔ¼ì²âÔÚ¿¹ÄýÒ©Îï¼à²âÖеÄÓ¦ÓÃ[J].±ê¼ÇÃâÒ߯ÊÎöÓëÁÙ´²,2020,27(8):1444-1449.

[3] Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl): e737S-e801S.

[4] ÕźèÑÞ,Èξ²,ÃŽ£Áú.¿¹ÄýÒ©ÎïµÄʵÑéÊÒ¼à²â[J].ÖйúÐÄѪ¹ÜÔÓÖ¾,2019,24(6):565-570.

[5] Vandiver J W , Vondracek T G . Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin[J]. Pharmacotherapy, 2012, 32(6):546-558.

[6] The Extracorporeal Life Support Organization (ELSO).ELSO Anticoagulation Guideline.2014, 1-17.

[7] Babin JL, Traylor KL, Witt DM. Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. Semin Thromb Hemost. 2017 Apr;43(3):261-269.

[8] ëøæÂ,ÀîÓÂÄÐ,Â¥ËÉ.¿¹Xa»îÐÔÔÚͨË׸ÎËØ¿¹Äý¼à²âÖÐÓ¦ÓõÄÑо¿Ï£Íû[J].ÖйúÌåÍâÑ­»·ÔÓÖ¾,2018,16(4):248-251.

[9] Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265-72. 

ÉÏÏ»¬¶¯Éó²éÍêÕû²Î¿¼ÎÄÏ×





END

ÎÄÕÂȪԴ£º²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éÉúÎï

Ôð±à£ºEcho

У¶Ô£ºÐ¡¾Å¡¢Pretty



 
ÍøÕ¾µØÍ¼